Key Publications

Subscribe to get the latest clinical and R&D news

Thanks! You're subscribed.
Oops! Something went wrong while submitting the form.

Ovarian

  • Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy
    Nov 2021
    — by
    Sliheet, E; Robinson, M; Morand, S; Choucair, K; Willoughby, D; Stanbery, L; Aaron, P, Bognar, E; Nemunaitis, J
  • Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer
    Oct 2021
    — by
    Walter, A; Rocconi, RP; Monk, BJ; Herzog, TJ; Manning, L; Bognar, E; Wallraven, G; Aaron, P; Horvath, S; Tang, M; Stanbery, L; Coleman, RL; Nemuanitis, J
  • Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer
    Aug 2021
    — by
    Rocconi, R.P.; Stanbery, L.; Madeira da Silva, L.; Barrington, R.A.; Aaron, P.; Manning, L.; Horvath, S.; Wallraven, G.; Bognar, E.; Walter, A.; Nemunaitis, J.
  • Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer
    Mar 2021
    — by
    Rocconi RP, Stevens EE, Bottsford-Miller JN, Ghamande SA, Elder J, DeMars LL, MunkarahA, Aaron P, Stanbery L, Wallraven G, Bognar E, Manley M, Horvath S, Manning L,Walter A, Galanis E, Herzog T, Monk BJ, Coleman RL, Nemunaitis J.
  • Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer
    Mar 2021
    — by
    Rocconi RP, Monk BJ, Walter A, Herzog TJ, Galanis E, Manning L, Bognar E, Wallraven G, Stanbery L, Aaron P, Senzer N, Coleman RL, Nemunaitis J.
  • Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial
    Dec 2020
    — by
    Rocconi R, Grosen E, Ghamande S, Chan J, Barve M, Oh J, Tewari D, Morris P, Stanberry L, Horvath S, Wallraven G, Bognar E, Manning L, Nemunaitis J, Shanahan D, Slomovitz B, Herzog T, Monk B, Coleman R
  • Long-term Follow-up of Phase 2A Trial Results Involving Advanced Ovarian Cancer Patients Treated with Vigil® in Frontline Maintenance
    Sep 2020
    — by
    Oh J, Barve M, Senzer N, Aaron P, Manning L, Wallraven G, Bognar E, Stanbery L, Horvath S, Manley M, Nemunaitis J, Walter A, Rocconi RP
  • Phase II Study of Vigil DNA Engineered Immunotherapy as Maintenance in Advanced Stage Ovarian Cancer. Gynecologic Oncology
    Dec 2016
    — by
    Oh J, Barve M, Matthews CM, Koon EC, Heffernan EP, Fine B, Grosen E, Bergman MK, Fleming EL, DeMars LR, West L, Spitz DL, Goodman H, Hancock KC, Wallraven G, Kumar P, Bognar E, Manning L, Pappen BO, Adams N, Senzer N, Nemunaitis J

    Ewing’s

    • Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy
      May 2017
      — by
      Ghisoli M, Rutledge M, Stephens P, Mennel R, Barve M, Manley M, Oliai B, Murphy K, Manning L, Gutierrez B, Rangadass P, Walker A, Wang Z, Rao D, Adams N, Wallraven G, Senzer N, Nemunaitis J

    • Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma
      May 2016
      — by
      Rao D, Jay C, Wang Z, Luo X, Kumar P, Eysenbach H, Ghisoli M, Senzer N, NemunaitisJJ

    • Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma
      Apr 2016
      — by
      Ghisoli M, Barve M, Mennel R, Lenarsky C, Horvath S, Wallraven G, Pappen BO, Whiting S, Rao D, Senzer N, Nemunaitis J

    • Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma
      Mar 2015
      — by
      Ghisoli M, Barve M, Schneider R, Mennel R, Lenarsky C, Wallraven G, Pappen BO, LaNoue J, Kumar P, Nemunaitis D, Roth A, Nemunaitis J, Whiting S, Senzer N, Fletcher FA, Nemunaitis J

    • Ewing’s Sarcoma: Development of RNA Interference Based Therapy for Advanced Disease
      Mar 2012
      — by
      Simmons O, Maples PB, Senzer N, Nemunaitis J

      Phase 1 Advanced Solid Tumor

      • Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer
        Aug 2021
        — by
        Rocconi, R.P.; Stanbery, L.; Madeira da Silva, L.; Barrington, R.A.; Aaron, P.; Manning, L.; Horvath, S.; Wallraven, G.; Bognar, E.; Walter, A.; Nemunaitis, J.

      • Vigil: Personalized Immunotherapy Generating Systemic Cytotoxic T Cell Response
        Oct 2020
        — by
        Herron J, Smith N, Stanbery L, Aaron P, Manning L, Bognar E, Wallraven G, Horvath S, Nemunaitis J

      • Assessment of Low Dose Vigil® Engineered Autologous Tumor Cell (EATC) Immunotherapy in Patients with Advanced Solid Tumors
        Apr 2017
        — by
        Manning L, Barve M, Wallraven G, Kumar P, Taquet N, Bognar E, Mendeloff E, Oh J, Rao D, Pappen BO, Senzer N, Nemunaitis J

      • Preclinical Biodistribution and Safety Evaluation of a pbi-shRNA STMN1 Lipoplex after Subcutaneous Delivery
        Nov 2016
        — by
        Wang Z, Jay C, Evans C, Kumar P, Phalon C, Rao D, Senzer N, Nemunaitis J

      • Immune response and survival of refractory cancer patients who received TGF-β2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine
        Mar 2013
        — by
        Nemunaitis J, Senzer N, Olivares J, Kumar P, Barve M, Kuhn J, Nemunaitis T, Magee M, Yu Y, Wallraven G, Pappen BO, Maples PB

      • Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer
        Dec 2011
        — by
        Senzer N, Barve M, Kuhn J, Melnyk A, Beitsch P, Lazar M, Lifshitz S, Magee M, Oh J, Mill SW, Bedell C, Higgs C, Kumar P, Yu Y, Norvell F, Phalon C, Taquet N, Rao DD, Wang Z, Jay CM, Pappen BO, Wallraven G, Brunicardi FC, Shanahan DM, Maples PB, Nemunaitis J

      • In vivo Safety and Antitumor Efficacy of Bifunctional Small Hairpin RNAs Specific for the Human Stathmin 1 Oncoprotein
        Sep 2011
        — by
        Phadke AP, Jay CM, Wang Z, Chen S, Liu S, Haddock C, Kumar P, Pappen BO, Rao DD, Templeton NS, Daniels EQ, Webb C, Monsma D, Scott S, Dylewski D, Frieboes HB, Brunicardi FC, Senzer N, Maples PB, Nemunaitis J, Tong AW

      • Phase I Trial of TGF-β2 Antisense GM-CSF Gene-Modified Autologous Tumor Cell (TAG) Vaccine
        Jan 2011
        — by
        Olivares J, Kumar P, Yu Y, Maples PB, Senzer N, Bedell C, Barve M, Tong A, Pappen BO, Kuhn J, Magee M, Wallraven G, Nemunaitis J

        Head and Neck

        • Relationships of clinical response to relevant molecular signal during Phase I testing of Aurora Kinase A inhibitor: Retrospective assessment
          Aug 2015
          — by
          Nemunaitis J, Blend C, Bien-Willner G, Degele M, Roth A, Hayes S, Plato L, Guo A, Nemunaitis J, Jackson DB, Senzer N

        • Immune response and survival of refractory cancer patients who received TGF-β2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine
          Mar 2013
          — by
          Nemunaitis J, Senzer N, Olivares J, Kumar P, Barve M, Kuhn J, Nemunaitis T, Magee M, Yu Y, Wallraven G, Pappen BO, Maples PB

          Lung Cancer

          • Induction of Immune Responses and Clinical Efficacy in a Phase II Trial of IDM-2101, a 10-Epitope Cytotoxic T-Lymphocyte Vaccine, in Metastatic Non–Small-Cell Lung Cancer
            Sep 2016
            — by
            Barve M, Bender J, Senzer N, Cunningham C, Greco FA, McCune D, Steis R, Khong H, Richards D, Stephenson J, Ganesa P, Nemunaitis J, Ishioka G, Pappen B, Nemunaitis M, Morse M, Mills B, Maples PB, Sherman J, Nemunaitis J

          • Phase II trial of Belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients
            Mar 2009
            — by
            Nemunaitis J, Nemunaitis M, Senzer N, Snitz P, Bedell C, Kumar P, Pappen B, Maples PB, Shawler D, Fakhrai H

            Prostate Cancer

            • MicroRNA profile analysis of human prostate cancers
              Oct 2008
              — by
              Tong AW, Fulgham P, Jay C, Chen P, Khalil I, Liu S, Senzer N, Eklund AC, Han J, Nemunaitis J

              Hereditary Inclusion Body Myopathy

              • Hereditary Inclusion Body Myopathy: Single Patient Response to Intravenous Dosing of GNE Gene Lipoplex
                Feb 2011
                — by
                Nemunaitis G, Jay CM, Maples PB, Gahl WA, Huizing M, Yardeni T, Tong AW, Phadke AP, Pappen BO, Bedell C, Allen H, Hernandez C, Templeton NS, Kuhn J, Senzer N, Nemunaitis J

              • Hereditary inclusion body myopathy: single patient response to GNE gene Lipoplex therapy
                Mar 2010
                — by
                Nemunaitis G, Maples PB, Jay C, Gahl WA, Huizing M, Poling J, Tong AW, Phadke AP, Pappen BO, Bedell C, Templeton NS, Kuhn J, Senzer N, Nemunaitis J

              • Safety and in vivo Expression of a GNE-Transgene: A Novel Treatment Approach for Hereditary Inclusion Body Myopathy-2
                May 2009
                — by
                Phadke AP, Jay C, Chen SJ, Haddock C, Wang Z, Yu Y, Nemunaitis D, Nemunaitis G, Templeton NS, Senzer N, Maples PB, Tong AW, Nemunaitis J

                Pancreatic

                • KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex
                  May 2018
                  — by
                  Rao DD, Luo X, Wang Z, Jay CM, Brunicardi FC, Maltese WA, Manning LM, Senzer N, Nemunaitis J

                • Metformin Restrains Pancreatic Duodenal Homeobox-1 (PDX-1) Function by Inhibiting ERK Signaling in Pancreatic Ductal Adenocarcinoma
                  Jan 2016
                  — by
                  Zhou G, Yu J, Wang A, Liu SH, Sinnett-Smith J, Wu J, Sanchez R, Nemunaitis J, Ricordi C, Rozengurt E, Brunicardi FC

                  Melanoma

                  • Follow-up of bi-shRNA furin / GM-CSF Engineered Autologous Tumor Cell (EATC) Immunotherapy Vigil® in patients with advanced melanoma
                    Sep 2016
                    — by
                    Barve M, Kuhn J, Lamont J, Beitsch P, Manning L, Pappen BO, KumarP, Wallraven G, Senzer N, Nemunaitis J

                    Low Dose

                    • Assessment of Low Dose Vigil® Engineered Autologous Tumor Cell (EATC) Immunotherapy in Patients with Advanced Solid Tumors
                      Apr 2017
                      — by
                      Manning L, Barve M, Wallraven G, Kumar P, Taquet N, Bognar E, Mendeloff E, Oh J, Rao D, Pappen BO, Senzer N, Nemunaitis J

                      See how we can help

                      Contact us